| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,640,000 |
| Market
Cap: |
203.98(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.25 - $4.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Black Diamond Therapeutics is an oncology medicine company focusing on the discovery and development of small molecule, MasterKey therapies. Co.'s proprietary technology platform, which it refers to as its Mutation-Allostery-Pharmacology drug discovery engine, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Co. has designed its clinical-stage product candidates, BDTX-1535 and BDTX-189, to selectively inhibit families of oncogenic mutations which occur across a range of tumor types that affect the ErbB-1 epidermal growth factor receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
5,784,292 |
6,005,892 |
| Total Sell Value |
$0 |
$0 |
$11,997,749 |
$13,398,305 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
2 |
| End Date |
2025-08-03 |
2025-05-02 |
2024-11-01 |
2023-11-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Raman Prakash |
|
– • – |
2025-09-19 |
4 |
A |
$3.35 |
$12,874 |
D/D |
3,843 |
26,362 |
|
- |
|
| Behbahani Ali |
|
– • – |
2025-09-19 |
4 |
A |
$3.35 |
$14,375 |
D/D |
4,291 |
81,441 |
|
- |
|
| Raman Prakash |
|
– • – |
2025-06-20 |
4 |
A |
$2.33 |
$12,876 |
D/D |
5,526 |
22,519 |
|
- |
|
| Behbahani Ali |
|
– • – |
2025-06-20 |
4 |
A |
$2.33 |
$14,376 |
D/D |
6,170 |
77,150 |
|
- |
|
| Behbahani Ali |
|
– • – |
2025-03-21 |
4 |
A |
$1.88 |
$14,374 |
D/D |
7,646 |
70,980 |
|
- |
|
| Raman Prakash |
|
– • – |
2025-03-21 |
4 |
A |
$1.88 |
$12,874 |
D/D |
6,848 |
16,993 |
|
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2025-03-19 |
4 |
S |
$1.94 |
$11,997,749 |
D/D |
(5,784,292) |
2,733,547 |
|
-62% |
|
| Buck Elizabeth |
CHIEF SCIENTIFIC OFFICER |
• – – |
2025-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
170,192 |
|
- |
|
| Yurasov Sergey |
CHIEF MEDICAL OFFICER |
• – – |
2025-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
75,000 |
|
- |
|
| Velleca Mark A. |
PRESIDENT & CEO |
• • – |
2025-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
121,522 |
|
- |
|
| Jones Erika |
SEE REMARKS |
• – – |
2025-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
85,150 |
|
- |
|
| Hatzis-Schoch Brent |
SEE REMARKS |
• – – |
2025-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
83,400 |
|
- |
|
| Raman Prakash |
|
– • – |
2024-09-20 |
4 |
A |
$4.78 |
$12,877 |
D/D |
2,694 |
4,995 |
|
- |
|
| Campbell Shannon |
|
– • – |
2024-09-20 |
4 |
A |
$4.78 |
$11,252 |
D/D |
2,354 |
4,365 |
|
- |
|
| Behbahani Ali |
|
– • – |
2024-09-20 |
4 |
A |
$4.78 |
$14,373 |
D/D |
3,007 |
57,584 |
|
- |
|
| Versant Vantage I, L.p. |
|
– – • |
2024-08-28 |
4 |
S |
$6.32 |
$1,400,556 |
D/D |
(221,600) |
3,726,341 |
|
67% |
|
| Campbell Shannon |
|
– • – |
2024-06-21 |
4 |
A |
$4.98 |
$10,015 |
D/D |
2,011 |
2,011 |
|
- |
|
| Behbahani Ali |
|
– • – |
2024-06-21 |
4 |
A |
$4.98 |
$14,377 |
D/D |
2,887 |
54,577 |
|
- |
|
| Raman Prakash |
|
– • – |
2024-06-21 |
4 |
A |
$4.98 |
$11,459 |
D/D |
2,301 |
2,301 |
|
- |
|
| Dixon Wendy L |
|
– • – |
2024-03-15 |
4 |
A |
$4.54 |
$14,769 |
D/D |
3,253 |
38,054 |
|
- |
|
| Behbahani Ali |
|
– • – |
2024-03-15 |
4 |
A |
$4.54 |
$14,374 |
D/D |
3,166 |
51,690 |
|
- |
|
| Behbahani Ali |
Director |
– • – |
2023-12-15 |
4 |
A |
$2.73 |
$12,162 |
D/D |
4,455 |
48,524 |
|
- |
|
| Dixon Wendy L |
|
– • – |
2023-12-15 |
4 |
A |
$2.73 |
$11,037 |
D/D |
4,043 |
34,801 |
|
- |
|
| Bb Biotech Ag |
|
– – • |
2023-10-17 |
4 |
B |
$2.34 |
$934,080 |
D/D |
400,000 |
8,517,839 |
0.01 |
109% |
|
| Dixon Wendy L |
|
– • – |
2023-09-15 |
4 |
A |
$3.60 |
$10,750 |
D/D |
2,986 |
30,758 |
|
- |
|
301 Records found
|
|
Page 1 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.08 (2.07%) 
